← Back to Screener
Pyxis Oncology, Inc. Common Stock (PYXS)
Price$1.78
Growth ScoreD
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-73.63%
Price vs S&P 500 (4W)-35.03%
VGM Score41.15
Market Capitalization$112.77M
All Metrics
Book Value / Share (Quarterly)$0.50
P/TBV (Annual)1.34x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.07
Price vs S&P 500 (YTD)46.62%
EPS (TTM)$-0.93
10-Day Avg Trading Volume0.62M
EPS Excl Extra (TTM)$-0.93
EPS (Annual)$-1.28
ROI (Annual)-149.02%
Gross Margin (Annual)82.77%
Cash / Share (Quarterly)$0.65
ROA (Last FY)-87.00%
Revenue Growth TTM (YoY)-14.17%
EBITD / Share (TTM)$-0.92
ROE (5Y Avg)-75.19%
Cash Flow / Share (Annual)$-1.01
P/B Ratio3.61x
P/B Ratio (Quarterly)2.93x
Net Income / Employee (Annual)$-1,421,800
Net Interest Coverage (TTM)-10.80x
ROA (TTM)-49.30%
EPS Incl Extra (Annual)$-1.28
Current Ratio (Annual)3.41x
Quick Ratio (Quarterly)2.57x
3-Month Avg Trading Volume0.48M
52-Week Price Return43.55%
Revenue / Employee (TTM)$247,500
Tangible BV / Share (Quarterly)$0.85
P/S Ratio (Annual)8.14x
Asset Turnover (Annual)0.15x
52-Week High$5.55
EPS Excl Extra (Annual)$-1.28
CapEx CAGR (5Y)-63.96%
26-Week Price Return-65.70%
Quick Ratio (Annual)3.26x
13-Week Price Return31.85%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.76x
Enterprise Value$107.01M
Revenue / Employee (Annual)$247,500
Pretax Margin (Annual)-564.55%
Cash / Share (Annual)$1.07
3-Month Return Std Dev111.30%
Net Income / Employee (TTM)$-1,028,900
ROE (Last FY)-149.08%
Net Interest Coverage (Annual)-10.80x
EPS Basic Excl Extra (Annual)$-1.28
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.93
ROI (TTM)-70.75%
Revenue / Share (Annual)$0.22
Tangible BV / Share (Annual)$0.85
Price vs S&P 500 (52W)19.18%
Year-to-Date Return54.78%
5-Day Price Return-0.56%
EPS Normalized (Annual)$-1.28
ROA (5Y Avg)-52.58%
Net Profit Margin (Annual)-574.55%
Month-to-Date Return-1.11%
Cash Flow / Share (TTM)$-2.48
EBITD / Share (Annual)$-1.32
Operating Margin (Annual)-609.18%
ROI (5Y Avg)-75.17%
EPS Basic Excl Extra (TTM)$-0.93
P/TBV (Quarterly)1.34x
P/B Ratio (Annual)1.34x
Book Value / Share (Annual)$0.85
Price vs S&P 500 (13W)23.60%
Beta1.43x
Revenue / Share (TTM)$0.22
ROE (TTM)-70.80%
52-Week Low$0.97
gGradeD
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.37est. -0.38
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.33
4.33
4.33
4.33
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PYXSPyxis Oncology, Inc. Common Stock | — | D | C | $1.78 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Pyxis Oncology is a preclinical-stage company developing next-generation therapeutics targeting difficult-to-treat cancers. The company's dual approach combines direct tumor cell killing with addressing underlying cancer pathologies that enable proliferation and immune evasion. This strategy aims to improve treatment outcomes for patients with limited options.